Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Childhood Oligoastrocytoma Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma
Interventions
SU011248 & Irinotecan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced May 21, 2026, 4:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Anaplastic Ependymoma
Interventions
AXL1717
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Anaplastic Oligoastrocytoma
Interventions
E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Oligoastrocytoma
Interventions
Ad-RTS-hIL-12, veledimex
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions
DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8
Genetic · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
Interventions
Toca 511 vector, Toca FC
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
imetelstat sodium, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions
Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced May 21, 2026, 4:40 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma, Gliosarcoma
Interventions
ascorbic acid, temozolomide, quality-of-life assessment, laboratory biomarker analysis
Dietary Supplement · Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
Interventions
IL13-PE38QQR, targeted fusion protein therapy, surgery
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Denver, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2011 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Erlotinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Tumor, Adult Oligoastrocytoma
Interventions
tumor lysate-pulsed autologous dendritic cell vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
Interventions
Toca 511 vector, Toca FC
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced May 21, 2026, 4:40 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Malignant Gliomas
Interventions
Irinotecan, Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced May 21, 2026, 4:40 PM EDT
Active, not recruiting Phase 1 Interventional Results available
View directory record Official record
Conditions
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma, Recurrent WHO Grade III Glioma
Interventions
Carboxylesterase-expressing Allogeneic Neural Stem Cells, Irinotecan, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 4:40 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions
Plerixafor, Bevacizumab, Surgery
Drug · Procedure
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
Interventions
Interferon-beta
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor, Tumors Metastatic to Brain, Adult Anaplastic Oligoastrocytoma
Interventions
bafetinib, microdialysis, pharmacological study, liquid chromatography, mass spectrometry, laboratory biomarker analysis, protein expression analysis, western blotting, immunohistochemistry staining method, therapeutic conventional surgery
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced May 21, 2026, 4:40 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced May 21, 2026, 4:40 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma Multiforme, Astrocytoma, Gliomas, Malignant
Interventions
Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced May 21, 2026, 4:40 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Interventions
Nanoliposomal CPT-11
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced May 21, 2026, 4:40 PM EDT